Jove
Visualize
Contact Us

Related Experiment Videos

HIV treatment-associated hepatitis.

R Orenstein1, E LeGall-Salmon

  • 1HIV/AIDS Program, Hunter Holmes McGuire Veterans Affairs Medical Center, Richmond, Virginia 23249, USA.

The AIDS Reader
|May 10, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neuroinvasive St. Louis Encephalitis Virus Infection in Solid Organ Transplant Recipients.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2017
Same author

Successful colonoscopic fecal transplant for severe acute Clostridium difficile pseudomembranous colitis.

Revista de gastroenterologia de Mexico·2012
Same author

Melarsoprol-associated multifocal inflammatory CNS illness in African trypanosomiasis.

Neurology·2006
Same author

Hepatitis C virus and human immunodeficiency virus co-infection in women.

The Journal of the American Osteopathic Association·2002
Same author

The benefits and limitations of needle protectors and needleless intravenous systems.

Journal of intravenous nursing : the official publication of the Intravenous Nurses Society·2000
Same author

Bacterial complications of strongyloidiasis: Streptococcus bovis meningitis.

Southern medical journal·1999
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Patients with HIV disease on antiretroviral therapy face high risks for drug-induced hepatitis. Monitoring liver enzymes is crucial for early detection and management of this severe adverse drug reaction.

Area of Science:

  • Hepatology
  • Infectious Diseases
  • Pharmacology

Background:

  • Combination antiretroviral therapy (cART) is standard for HIV disease management.
  • cART and other prescribed medications increase the risk of adverse drug reactions and interactions.
  • Severe hepatitis is a known risk associated with all antiretroviral agent classes.

Purpose of the Study:

  • To review the incidence, clinical features, risk factors, and etiology of drug-induced hepatitis in patients with HIV disease.
  • To inform physicians about the risk of hepatocellular injury associated with antiretroviral therapy.
  • To emphasize the importance of monitoring transaminase levels in at-risk patients.

Main Methods:

  • Literature review of drug-induced hepatitis in the context of HIV treatment.

Related Experiment Videos

  • Analysis of clinical features and risk factors associated with specific antiretroviral combinations.
  • Examination of the etiological agents contributing to drug-induced liver injury.

    • Main Results:

    • All classes of antiretroviral agents have been associated with severe hepatitis.
    • Hepatocellular injury is a significant concern in patients undergoing antiretroviral therapy.
    • Various antiretroviral combinations present distinct risk profiles for drug-induced hepatitis.

    Conclusions:

    • Physicians must be vigilant regarding the potential for drug-induced hepatitis in HIV patients.
    • Regular monitoring of transaminase levels is essential for early identification of liver injury.
    • Understanding the etiology and risk factors aids in preventing and managing this adverse event.